ABEONA THERAPEUTICS INC.(ABEO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,716 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ABEO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ABEONA THERAPEUTICS INC. (ABEO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABEO at 23.7/100 on a 32-signal composite quality model, placing it at rank #2,716 of 2,961 stocks — the bottom half of the AI-ranked universe. ABEO scores in the top quartile across revenue growth (96.7). Areas of concern include free cash flow (3.3) and revenue scale (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ABEONA THERAPEUTICS INC. reports quarterly revenue of $11.4M, net income of $-20.2M, free cash flow of $-18.0M. Top institutional holders of ABEO by reported 13-F value include Nantahala Capital Management, BlackRock, Cable Car Capital, based on the most recent SEC filings. ABEO trades on the Nasdaq exchange and files with the SEC under CIK 318306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABEONA THERAPEUTICS INC. directly from SEC EDGAR. ABEONA THERAPEUTICS INC.'s 13F Pro composite quality score has ranged between 4 and 39 since 2021, currently 23.7 — a stable long-term trajectory across 37 quarterly and live scoring snapshots.
Revenue
Q2 2026
$11.4M
Net Income
Q2 2026
$-20.2M
Free Cash Flow
Q2 2026
$-18.0M
ROIC
Q2 2026
-34.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+211.7% YoYOperating Income
-39.3% YoYEPS (Diluted)
+165.2% YoYTotal Assets
+101.6% YoYTotal Debt
+29.6% YoYOp. Cash Flow
-36.3% YoYFree Cash Flow
-44.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.8M | — | $3.5M +147.5% | $1.4M -52.9% | $3.0M -70.0% | $10.0M |
| Net Income | $71.2M +211.7% | $-63.7M -17.6% | $-54.2M -36.5% | $-39.7M +53.3% | $-84.9M -0.8% | $-84.2M |
| Operating Income | $-89.4M -39.3% | $-64.2M -36.2% | $-47.1M +7.4% | $-50.9M +43.3% | $-89.8M -10.3% | $-81.4M |
| EPS (Diluted) | $1.01 +165.2% | $-1.55 +38.7% | $-2.53 +54.2% | $-5.53 | — | — |
| Total Assets | $219.6M +101.6% | $108.9M +70.2% | $64.0M -0.3% | $64.2M -19.3% | $79.6M -47.4% | $151.2M |
| Total Debt | $32.3M +29.6% | $24.9M | — | — | — | — |
| Operating Cash Flow | $-76.3M -36.3% | $-56.0M -51.4% | $-37.0M +14.9% | $-43.5M +33.8% | $-65.7M -87.5% | $-35.0M |
| Free Cash Flow | $-84.3M -44.2% | $-58.5M -56.6% | $-37.3M +14.4% | $-43.6M +37.5% | $-69.8M -92.0% | $-36.4M |
Get alerted when ABEO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ABEONA THERAPEUTICS INC. including:
Top Institutional Holders of ABEO
Nantahala Capital Management, LLC
$31.7M5,136,490 shBlackRock, Inc.
$20.7M3,352,474 shCable Car Capital, LP
$18.6M3,007,329 shAIGH Capital Management LLC
$18.5M2,987,000 shVANGUARD CAPITAL MANAGEMENT LLC
$13.7M2,211,433 shOneDigital Investment Advisors LLC
$10.2M1,653,024 shAWM Investment Company, Inc.
$9.2M1,486,130 shGEODE CAPITAL MANAGEMENT, LLC
$7.8M1,261,090 shKENNEDY CAPITAL MANAGEMENT LLC
$7.7M1,240,071 shGOLDMAN SACHS GROUP INC
$7.6M1,224,806 sh
| Fund | Value | Shares |
|---|---|---|
| Nantahala Capital Management, LLC | $31.7M | 5,136,490 |
| BlackRock, Inc. | $20.7M | 3,352,474 |
| Cable Car Capital, LP | $18.6M | 3,007,329 |
| AIGH Capital Management LLC | $18.5M | 2,987,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.7M | 2,211,433 |
| OneDigital Investment Advisors LLC | $10.2M | 1,653,024 |
| AWM Investment Company, Inc. | $9.2M | 1,486,130 |
| GEODE CAPITAL MANAGEMENT, LLC | $7.8M | 1,261,090 |
| KENNEDY CAPITAL MANAGEMENT LLC | $7.7M | 1,240,071 |
| GOLDMAN SACHS GROUP INC | $7.6M | 1,224,806 |
Companies Similar to ABEO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
DELCATH SYSTEMS, INC.
ORTHOPEDIATRICS CORP
Syndax Pharmaceuticals Inc
ARDELYX, INC.
MANNKIND CORP
CERUS CORP
UroGen Pharma Ltd.
Ovid Therapeutics Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ABEO on your watchlist
Track score changes the day ABEONA THERAPEUTICS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ABEO a good stock to buy?
13F Pro's AI-powered analysis of ABEONA THERAPEUTICS INC. (ABEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABEO are available on the ABEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABEO is classified as a small company.
Which hedge funds own ABEO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABEONA THERAPEUTICS INC.'s investment landscape.